Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About WST Interactive Breakdown Better Bets vs. WST Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

West Pharmaceutical Services (WST)

Market Price (10/23/2025): $284.0 | Market Cap: $20.5 Bil
Sector: Health Care | Industry: Health Care Supplies

West Pharmaceutical Services (WST)

Market Price (10/23/2025): $284.0
Market Cap: $20.5 Bil
Sector: Health Care
Industry: Health Care Supplies

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 21%		 Weak multi-year price returns
2Y Excs Rtn is -81%, 3Y Excs Rtn is -73%		 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 33x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 30x, P/EPrice/Earnings or Price/(Net Income) is 41x
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 23%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12%		  Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.4%
2 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -35%		  
0 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 21%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 23%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12%
2 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -35%
3 Weak multi-year price returns
2Y Excs Rtn is -81%, 3Y Excs Rtn is -73%
4 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 33x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 30x, P/EPrice/Earnings or Price/(Net Income) is 41x
5 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.4%

Market Valuation & Key Metrics

WSTS&P 500
REVENUE GROWTHPOOR
Rev LTM ($ Bil)3.0
Rev Chg Q9.2%6.1%
Rev Chg LTM2.9%5.2%
Rev Chg 3Y Avg0.4%5.4%
PROFITABILITYGOOD
Op Inc LTM ($ Bil)0.6
CFO LTM ($ Bil)0.7
Net Inc LTM ($ Bil)0.5
Op Mgn LTM21.0%18.6%
CFO/Rev LTM22.9%20.4%
Net Inc Mgn16.5%12.7%
VALUATIONVERY HIGH
P/S6.93.3
P/CFO30.316.1
P/FCF59.621.2
P/E42.024.5
STABILITYVERY GOOD
Debt/Equity0.010.21
Cash/Assets0.130.07

WST Stock

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
WST Return89%66%-50%50%-7%-15%83%
Peers Return20%10%2%-3%17%-5%46%
S&P 500 Return16%27%-19%24%23%14%106%

Monthly Win Rates [3]
WST Win Rate75%83%33%67%50%56% 
Peers Win Rate55%57%47%48%57%53% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
WST Max Drawdown-14%-9%-55%-1%-21%-42% 
Peers Max Drawdown-32%-7%-14%-21%-6%-16% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: RMD, PKG, AMCR, SLGN, SON. See WST Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/22/2025 (YTD)

How Low Can It Go

Unique KeyEventWSTS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-55.6%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven125.2%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-26.2%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven35.5%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven31 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-25.0%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven33.3%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven186 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-45.6%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven83.7%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1295 days1480 days

Compare to RMD, PKG, AMCR, SLGN, SON


In The Past

West Pharmaceutical Services's stock fell -55.6% during the 2022 Inflation Shock from a high on 12/30/2021. A -55.6% loss requires a 125.2% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About West Pharmaceutical Services (WST)

Better Bets than West Pharmaceutical Services (WST)

 WSTBetter Performance than WST
MetricValueIndustry (Health Care Supplies)
Rev Chg LTM2.9%COO (6.4%), MMSI (8.2%), LNTH (5.7%), ICUI (3.0%), BLFS (37.6%)
Rev Chg 3Y Avg0.4%COO (7.9%), MMSI (8.0%), LNTH (34.3%), ICUI (10.7%), HAE (9.7%)
Op Mgn LTM21.0%LNTH (28.9%)
CFO/Rev LTM22.9%LNTH (34.7%)
FCF/Rev LTM11.6%ALGN (15.9%), MMSI (12.8%), LNTH (31.1%), HAE (14.1%), BLFS (15.0%)
Total Yield2.6%COO (2.7%), ALGN (4.4%), LNTH (6.9%), HAE (6.6%)
 WSTBetter Performance than WST
MetricValueAll Other Sectors
Rev Chg LTM2.9%NVDA (71.6%), MSFT (14.9%), AAPL (6.0%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg0.4%NVDA (92.0%), MSFT (12.5%), AAPL (1.8%), GOOGL (10.2%), AMZN (11.3%)
Op Mgn LTM21.0%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM22.9%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), META (56.4%)
FCF/Rev LTM11.6%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), META (30.7%)
Total Yield2.6%MSFT (3.3%), AAPL (3.0%), GOOGL (4.1%), AMZN (3.0%), META (3.9%)
null

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1West Pharmaceutical Services Earnings Notes  
2How Low Can West Pharmaceutical Services Stock Really Go?Return 
3West Pharmaceutical Services vs Apple: Which Is A Better Investment?Counter-Intuitive Comparisons 
4West Pharmaceutical Services vs Johnson & Johnson: Which Is A Better Investment?Counter-Intuitive Comparisons 
5West Pharmaceutical Services vs Lantheus: Which Is A Better Investment?Counter-Intuitive Comparisons 
6How Does West Pharmaceutical Services Stock Stack Up Against Its Peers?Peer Comparison 
7Better Bet Than WST Stock: Pay Less Than West Pharmaceutical Services To Get More From AAPL, GOOGL   
8Better Bet Than WST Stock: Pay Less Than West Pharmaceutical Services To Get More From UNH, MRK   
9Better Bet Than WST Stock: Pay Less Than West Pharmaceutical Services To Get More From COO, HAE   
10Day 5 of Loss Streak for West Pharmaceutical Services Stock with -14% Return (vs. -27% YTD) [7/31/2025]Notification 
11ARTICLES  
12WST Stock Down -14% after 5-Day Loss Streak August 1st, 2025
13S&P 500 Movers | Winners: WST, URI, LH | Losers: LKQ, DOW, MOH July 25th, 2025
14Market Movers | Winners: BE, WST, ICLR | Losers: CYH, NVCR, IRDM July 25th, 2025
15Why Did West Pharmaceutical Services Stock Drop Almost 40%? February 14th, 2025
16Is There A Better Pick Over West Pharmaceutical Services Stock? March 10th, 2022
Title
0DASHBOARDS
1WST Stock Down -14% after 5-Day Loss Streak
2S&P 500 Movers | Winners: WST, URI, LH | Losers: LKQ, DOW, MOH
3Market Movers | Winners: BE, WST, ICLR | Losers: CYH, NVCR, IRDM
4Why Did West Pharmaceutical Services Stock Drop Almost 40%?
5Is There A Better Pick Over West Pharmaceutical Services Stock?
6ARTICLES
7West Pharmaceutical Services Earnings Notes
8How Low Can West Pharmaceutical Services Stock Really Go?
9West Pharmaceutical Services vs Apple: Which Is A Better Investment?
10West Pharmaceutical Services vs Johnson & Johnson: Which Is A Better Investment?
11West Pharmaceutical Services vs Lantheus: Which Is A Better Investment?
12How Does West Pharmaceutical Services Stock Stack Up Against Its Peers?
13Better Bet Than WST Stock: Pay Less Than West Pharmaceutical Services To Get More From AAPL, GOOGL 
14Better Bet Than WST Stock: Pay Less Than West Pharmaceutical Services To Get More From UNH, MRK 
15Better Bet Than WST Stock: Pay Less Than West Pharmaceutical Services To Get More From COO, HAE 
16Day 5 of Loss Streak for West Pharmaceutical Services Stock with -14% Return (vs. -27% YTD) [7/31/2025]

Trade Ideas

Select past ideas related to WST. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		0.4%0.4%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.0%3.0%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.3%6.3%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		16.1%16.1%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-0.9%-0.9%-8.0%
WST_8312025_Monopoly_xInd_xCD_Getting_Cheaper08312025WSTWest Pharmaceutical ServicesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		13.1%13.1%-1.3%
WST_2282025_Monopoly_xInd_xCD_Getting_Cheaper02282025WSTWest Pharmaceutical ServicesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		6.5%20.5%-18.1%
WST_8312024_Monopoly_xInd_xCD_Getting_Cheaper08312024WSTWest Pharmaceutical ServicesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-25.8%-21.0%-39.2%
WST_10312022_Dip_Buyer_High_CFO_Margins_ExInd_DE10312022WSTWest Pharmaceutical ServicesDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		59.4%38.7%-9.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		0.4%0.4%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.0%3.0%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.3%6.3%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		16.1%16.1%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-0.9%-0.9%-8.0%
WST_8312025_Monopoly_xInd_xCD_Getting_Cheaper08312025WSTWest Pharmaceutical ServicesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		13.1%13.1%-1.3%
WST_2282025_Monopoly_xInd_xCD_Getting_Cheaper02282025WSTWest Pharmaceutical ServicesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		6.5%20.5%-18.1%
WST_8312024_Monopoly_xInd_xCD_Getting_Cheaper08312024WSTWest Pharmaceutical ServicesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-25.8%-21.0%-39.2%
WST_10312022_Dip_Buyer_High_CFO_Margins_ExInd_DE10312022WSTWest Pharmaceutical ServicesDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		59.4%38.7%-9.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1PRAXPraxis Precision Medicines221.6%139.6%
2VICRVicor49.6%77.5%
3CCOClear Channel Outdoor41.2%40.1%
4CELCCelcuity40.0%435.1%
5WGOWinnebago Industries34.9%-11.6%
6BALYBallys27.4%-2.4%
7TFINTriumph Financial27.3%-32.9%
8SIONSionna Therapeutics25.8% 
9LVWRLiveWire24.4%29.1%
10PMIPicard Medical24.4%20804.8%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1BITFBitfarms-39.1%164.4%
2QBTSD-Wave Quantum-39.1%224.9%
3RGTIRigetti Computing-36.0%136.3%
4SMRNuScale Power-35.0%93.6%
5RCATRed Cat-31.9%-22.3%
6BKSYBlackSky Technology-31.3%101.3%
7OKLOOklo-30.0%465.8%
8QUBTQuantum Computing-30.0%-10.2%
9SESSES AI-29.9%13.2%
10ASPIASP Isotopes-29.4%96.7%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1366.7%342.6%
2QUREuniQure338.6%239.2%
3PRAXPraxis Precision Medicines279.5%139.6%
4LACLithium Americas117.9%125.3%
5CLPTClearPoint Neuro99.8%57.9%
6NVTSNavitas Semiconductor97.7%281.1%
7UAMYUnited States Antimony79.6%640.7%
8ORKAOruka Therapeutics71.3%37.4%
9GRALGRAIL69.8%346.8%
10TSHATaysha Gene Therapies69.2%185.5%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1SOCSable Offshore-51.7%-48.4%
2FLYFirefly Aerospace-37.4% 
3UPWheels Up Experience-37.0%-12.1%
4VGVenture Global-34.5% 
5PSIXPower Solutions International-33.0%160.7%
6ALABAstera Labs-32.7%16.9%
7FWRDForward Air-30.6%-41.0%
8QUBTQuantum Computing-30.5%-10.2%
9AEHRAehr Test Systems-29.6%42.4%
10TIPTTiptree-29.0%-15.1%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1PRAXPraxis Precision Medicines221.6%139.6%
2VICRVicor49.6%77.5%
3CCOClear Channel Outdoor41.2%40.1%
4CELCCelcuity40.0%435.1%
5WGOWinnebago Industries34.9%-11.6%
6BALYBallys27.4%-2.4%
7TFINTriumph Financial27.3%-32.9%
8SIONSionna Therapeutics25.8% 
9LVWRLiveWire24.4%29.1%
10PMIPicard Medical24.4%20804.8%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1BITFBitfarms-39.1%164.4%
2QBTSD-Wave Quantum-39.1%224.9%
3RGTIRigetti Computing-36.0%136.3%
4SMRNuScale Power-35.0%93.6%
5RCATRed Cat-31.9%-22.3%
6BKSYBlackSky Technology-31.3%101.3%
7OKLOOklo-30.0%465.8%
8QUBTQuantum Computing-30.0%-10.2%
9SESSES AI-29.9%13.2%
10ASPIASP Isotopes-29.4%96.7%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for West Pharmaceutical Services

Financials

WSTRMDPKGAMCRSLGNSONMedian
NameWest Pha.ResMed Packagin.Amcor Silgan Sonoco P. 
Mkt Price277.00266.48208.748.1444.5941.49126.67
Mkt Cap20.039.018.616.54.84.117.6
Rev LTM2,9605,1468,64115,0096,1625,6645,913
Op Inc LTM6221,6871,2891,316621448956
FCF LTM3441,65162581057143485
FCF 3Y Avg3661,166704791219301535
CFO LTM6771,7521,2911,390344544984
CFO 3Y Avg7121,2821,3321,324467676997

Growth & Margins

WSTRMDPKGAMCRSLGNSONMedian
NameWest Pha.ResMed Packagin.Amcor Silgan Sonoco P. 
Rev Chg LTM2.9%9.8%9.0%10.0%5.5%23.3%9.4%
Rev Chg 3Y Avg0.4%12.9%1.0%1.3%0.6%-3.0%0.8%
Rev Chg Q9.2%10.2%4.6%43.8%11.4%49.4%10.8%
QoQ Delta Rev Chg LTM2.2%2.5%1.1%11.5%2.6%12.6%2.6%
Op Mgn LTM21.0%32.8%14.9%8.8%10.1%7.9%12.5%
Op Mgn 3Y Avg22.2%29.9%14.6%9.3%10.2%9.1%12.4%
QoQ Delta Op Mgn LTM0.5%0.7%0.3%-1.7%0.2%0.6%0.4%
CFO/Rev LTM22.9%34.0%14.9%9.3%5.6%9.6%12.3%
CFO/Rev 3Y Avg24.6%26.8%16.3%9.2%7.8%13.1%14.7%
FCF/Rev LTM11.6%32.1%7.2%5.4%0.9%2.5%6.3%
FCF/Rev 3Y Avg12.6%24.3%8.6%5.5%3.7%5.9%7.3%

Valuation

WSTRMDPKGAMCRSLGNSONMedian
NameWest Pha.ResMed Packagin.Amcor Silgan Sonoco P. 
Mkt Cap20.039.018.616.54.84.117.6
P/S6.87.62.21.10.80.71.6
P/EBIT33.523.115.015.88.515.115.4
P/E41.027.920.632.315.87.424.2
P/CFO29.622.314.411.913.97.614.2
Total Yield2.6%4.4%7.3%8.2%8.1%18.5%7.7%
Dividend Yield0.2%0.8%2.4%5.1%1.8%5.0%2.1%
FCF Yield 3Y Avg1.7%3.6%4.9%5.1%4.7%5.9%4.8%
D/E0.00.00.20.91.11.40.5
Net D/E-0.0-0.00.10.91.01.30.5

Returns

WSTRMDPKGAMCRSLGNSONMedian
NameWest Pha.ResMed Packagin.Amcor Silgan Sonoco P. 
1M Rtn9.8%-2.9%-1.9%-1.3%4.9%-9.7%-1.6%
3M Rtn21.9%-2.3%1.8%-15.7%-20.0%-13.8%-8.0%
6M Rtn27.2%24.8%14.4%-11.9%-11.5%-6.3%4.1%
12M Rtn-3.0%12.0%-1.3%-21.8%-11.4%-17.4%-7.2%
3Y Rtn19.8%23.2%95.0%-16.2%3.8%-25.1%11.8%
1M Excs Rtn9.8%-4.0%-3.0%-0.0%5.5%-9.7%-1.5%
3M Excs Rtn-6.0%-7.6%-3.3%-20.6%-24.4%-18.9%-13.3%
6M Excs Rtn2.6%0.2%-10.2%-36.6%-36.1%-30.9%-20.6%
12M Excs Rtn-19.5%-2.2%-17.1%-37.8%-27.9%-32.3%-23.7%
3Y Excs Rtn-72.9%-54.7%14.5%-96.0%-75.9%-106.2%-74.4%

Comparison Analyses

Title
0How Does West Pharmaceutical Services Stock Stack Up Against Its Peers?
1BAX Could Deliver 20% Returns And Outperform WST
2With 12% Gains On The Table, WST May Outshine PKG
3SLGN Looks Stronger Than WST With 14% Return Potential
4West Pharmaceutical Services vs. Dominion Resources: With Return Forecast Of 80%, Dominion Resources Is A Better Bet
5West Pharmaceutical Services vs. Fidelity National Information Services: With Return Forecast Of 19%, Fidelity National Information Services Is A Better Bet
6West Pharmaceutical Services vs. Transdigm Group: With Return Forecast Of 50%, Transdigm Group Is A Better Bet
7West Pharmaceutical Services vs. Arista Networks: Similar Revenue, Similar Bets
8West Pharmaceutical Services vs. Match Group: Similar Revenue, Similar Bets
9West Pharmaceutical Services vs. DexCom: Similar Revenue, But DexCom Is A Better Bet

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date7/24/20254/24/20252/18/202510/24/20247/25/20244/25/20242/20/202410/26/20237/27/20234/27/20232/21/202310/27/2022
Key Financials Quarterly            
Total Revenue766698749747702695732747754717709687
Ebitda198151205205169165205226222192162168
Operating Income159128170166130126170183186168160188
Net Income13290130136111115137161155140103121
EPS1.821.241.791.871.521.571.852.172.081.881.381.62
Key Financials TTM            
Total Revenue TTM2,9602,8962,8932,8762,8772,9292,9502,9262,8662,8842,8872,909
Ebitda TTM760730744744765817844800743780808866
Operating Income TTM622593591591608665707698703742761789
Net Income TTM488467493500525569593559519552586631
Growth Rates Quarterly            
Total Revenue Growth9.2%0.4%2.3%-0.1%-6.9%-3.0%3.3%8.8%-2.3%-0.5%-3.0%-2.8%
EBITDA Growth17.4%-8.3%-0.2%-9.0%-23.7%-14.1%27.1%34.1%-14.4%-12.7%-26.2%-21.0%
Operating Income Growth22.7%1.4%0.0%-9.4%-30.6%-25.1%5.8%-2.8%-17.3%-9.9%-15.0%2.7%
Net Income Growth18.4%-22.1%-5.0%-15.7%-28.2%-17.6%33.0%33.7%-17.7%-19.4%-30.3%-31.3%
Margins Quarterly            
EBITDA Margin25.9%21.6%27.4%27.5%24.1%23.7%28.0%30.2%29.4%26.8%22.8%24.5%
Operating Income Margin20.7%18.3%22.7%22.2%18.4%18.1%23.2%24.5%24.7%23.5%22.6%27.4%
Net Income Margin17.2%12.9%17.4%18.2%15.9%16.6%18.7%21.6%20.6%19.5%14.5%17.6%
Cash & Debt            
Total Cash510404485491446602854899796886894729
Total Debt303303302305311307309307311314318300
Net Debt / (Cash)-206-101-182-186-136-295-545-592-485-572-576-429
Cash Flows Quarterly            
FCF from Operations177129190180165118239230169138231169
Cash Flows TTM            
FCF from Operations TTM677665653702752757776768707711724654
Returns to Shareholders Quarterly            
Dividends151515141515151414141414
Share Repurchases013655521872721772817472-028
Return on Invested Capital (ROIC) Quarterly            
ROIC------------
Return on Invested Capital (ROIC) TTM            
ROIC TTM------------

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Proprietary Products2,3972,4072,3171,6491,399
Contract-Manufactured Products552480515499442
Intersegment sales elimination0-0-0-0-0
Total2,9502,8872,8322,1471,840


Operating Income by Segment
$ Mil20242023202220212020
Proprietary Products710784796434314
Contract-Manufactured Products7260676949
Restructuring and related charges2-24-2  
Amortization of acquisition-related intangible assets-1-1-1  
Cost investment activity-4-4-4  
Loss on disposal of plant-1200  
Stock Based Compensation-23-24-38  
Corporate general costs-68-59-63  
Asset impairment  -3  
Intersegment sales elimination   -96-66
Total676734752407297


Assets by Segment
$ Mil20242023202220212020
Proprietary Products2,629  1,7981,481
Corporate and Unallocated673  584475
Contract-Manufactured Products528  412386
Total3,830  2,7942,341


Price Behavior

WST Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta1.420.490.700.710.570.83
Up Beta2.610.39-1.960.590.500.87
Down Beta-0.51-0.38-0.830.490.550.66
Up Capture164%97%238%109%34%49%
Bmk +ve Days13233574144420
Stock +ve Days10182655114363
Down Capture129%44%184%111%82%99%
Bmk -ve Days8192952107330
Stock -ve Days11223669135386

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date9302025
Short Interest: Shares Quantity1,674,945
Short Interest: % Change Since 9152025-0.2%
Average Daily Volume680,482
Days-to-Cover Short Interest2.46
Basic Shares Quantity72,200,000
Short % of Basic Shares2.3%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/24/202522.8%9.6%6.7%
4/24/2025-3.5%-3.1%-4.3%
2/13/2025-38.2%-36.8%-28.6%
10/24/202415.4%9.3%12.1%
7/25/2024-14.4%-5.4%-7.1%
4/25/2024-4.5%-5.8%-14.8%
2/15/2024-14.1%-11.8%-5.0%
10/26/2023-8.6%-10.1%-1.3%
...
SUMMARY STATS   
# Positive111211
# Negative131213
Median Positive6.1%6.5%7.9%
Median Negative-4.5%-5.2%-7.1%
Max Positive22.8%11.8%24.0%
Max Negative-38.2%-36.8%-28.6%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025724202510-Q 6/30/2025
3312025424202510-Q 3/31/2025
12312024218202510-K 12/31/2024
93020241024202410-Q 9/30/2024
6302024725202410-Q 6/30/2024
3312024425202410-Q 3/31/2024
12312023220202410-K 12/31/2023
93020231026202310-Q 9/30/2023
6302023727202310-Q 6/30/2023
3312023427202310-Q 3/31/2023
12312022221202310-K 12/31/2022
93020221027202210-Q 9/30/2022
6302022728202210-Q 6/30/2022
3312022428202210-Q 3/31/2022
12312021222202210-K 12/31/2021
93020211028202110-Q 9/30/2021

Insider Activity

Expand for More

 

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.